Vaccination in paediatric rheumatology

Current Rheumatology Reports

Volumn 16, Issue 8, 2014, Pages

  Akikusa, Jonathan D ^a,b   Crawford, Nigel W ^a,b,c  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Corticosteroid; DMARD; EULAR; European league against rheumatism; HPV; Human papillomavirus vaccine; Immunosuppression; Live vaccines; MMR booster; Non live vaccines; Paediatric rheumatic diseases; Pandemic influenza vaccination; PRDs; Vaccine preventable diseases

Indexed keywords

AZATHIOPRINE; CHOLERA VACCINE; CYCLOSPORIN; DIPHTHERIA VACCINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; IMMUNOSUPPRESSIVE AGENT; INFLUENZA VACCINE; JAPANESE ENCEPHALITIS VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; MERCAPTOPURINE; METHOTREXATE; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; RABIES VACCINE; RITUXIMAB; SALAZOSULFAPYRIDINE; TETANUS TOXOID; TICK BORNE ENCEPHALITIS VACCINE; TUMOR NECROSIS FACTOR ANTIBODY; TYPHOID VACCINE; UNINDEXED DRUG; VARICELLA ZOSTER VACCINE; WART VIRUS VACCINE; YELLOW FEVER VACCINE; LIVE VACCINE;

ANTIBODY TITER; ARTHRALGIA; ASPLENIA; COXITIS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HUMAN; HYPOCOMPLEMENTEMIA; IMMUNE DEFICIENCY; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; INJECTION SITE PRURITUS; JUVENILE DERMATOMYOSITIS; JUVENILE RHEUMATOID ARTHRITIS; LOW DRUG DOSE; PEDIATRIC RHEUMATIC DISEASE; PEDIATRICS; PRACTICE GUIDELINE; PREVALENCE; REVIEW; RHEUMATIC DISEASE; RHEUMATOLOGY; SCLERODERMA; SEROCONVERSION; SEROLOGY; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VACCINATION; VACCINE FAILURE; VIRUS INFECTION; VIRUS STRAIN; CHILD; COMPLICATION; IMMUNOLOGY; OPPORTUNISTIC INFECTIONS;

CHILD; HUMANS; IMMUNOCOMPROMISED HOST; INFLUENZA VACCINES; MEASLES-MUMPS-RUBELLA VACCINE; OPPORTUNISTIC INFECTIONS; PAPILLOMAVIRUS VACCINES; PRACTICE GUIDELINES AS TOPIC; RHEUMATIC DISEASES; VACCINATION; VACCINES, ATTENUATED;

EID: 84902038437     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-014-0432-9     Document Type: Review

References (29)

1. Davies K, Woo P. British Paediatric Rheumatology G Immunization in rheumatic diseases of childhood: an audit of the clinical practice of British Paediatric Rheumatology Group members and a review of the evidence. Rheumatology (Oxford). 2002;41(8):937-41.
2. Papadopoulou D. Sipsas NV Comparison of national clinical practice guidelines and recommendations on vaccination of adult patients with autoimmune rheumatic diseases. Rheumatol Int. 2014;34(2):151-63.
3. Morin MP, Quach C, Fortin E, et al. Vaccination coverage in children with juvenile idiopathic arthritis followed at a paediatric tertiary care centre. Rheumatology (Oxford). 2012;51(11):2046-50.
4. McCarthy EM, Azeez MA, Fitzpatrick FM, et al. Knowledge, attitudes, and clinical practice of rheumatologists in vaccination of the at-risk rheumatology patient population. J Clin Rheumatol. 2012;18(5):237-41.
5. .•• Heijstek MW, de Bruin LM O, Bijl M, et al. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis. 2011;70(10):1704-12. Presents the recommendations of the EULAR working group on vaccinations in PRDs - the most comprehensive effort to provide evidence-based recommendations in this field to date.
6. .• van Assen S, Agmon-Levin N, Elkayam O, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011;70(3):414-22. Presents the recommendations of the EULAR working group on vaccinations in adult rheumatic diseases and provides useful context for the paediatric recommendations.
7. .•• Heijstek MW, de Bruin LM O, Borrow R, et al. Vaccination in paediatric patients with auto-immune rheumatic diseases: a systemic literature review for the European League against Rheumatism evidence-based recommendations. Autoimmun Rev. 2011;11(2):112-22. Provides details of the search method and of the papers used to derive the subsequent EULAR recommendations for vaccination in PRDs.
8. van Assen S, Elkayam O, Agmon-Levin N, et al. Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases. Autoimmun Rev. 2011;10(6):341-52.
9. WHO. Summary of WHO position papers - Recommendations for Routine Immunisation. 2014 [cited 2014 28 April]; Available from: http://www.who.int/ immunization/policy/Immunization-routine-table1.pdf?ua=1.
10. Korematsu S, Miyahara H, Kawano T, et al. A relapse of systemic type juvenile idiopathic arthritis after a rubella vaccination in a patient during a long-term remission period. Vaccine. 2009;27(37):5041-2.
11. Linnemann Jr CC, Levinson JE, Buncher CR, et al. Rubella antibody levels in juvenile rheumatoid arthritis. Ann Rheum Dis. 1975;34(4):354-8.
12. Banovic T, Yanilla M, Simmons R, et al. Disseminated varicella infection caused by varicella vaccine strain in a child with low invariant natural killer T cells and diminished CD1d expression. J Infect Dis. 2011;204(12):1893-901.
13. Monafo WJ, Haslam DB, Roberts RL, et al. Disseminated measles infection after vaccination in a child with a congenital immunodeficiency. J Pediatr. 1994;124(2):273-6. (Pubitemid 24057798)
14. Sadeghi-Shabestari M. Rezaei N Disseminated bacille Calmette-Guerin in Iranian children with severe combined immunodeficiency. Int J Infect Dis. 2009;13(6):e420-3.
15. Heijstek MW, Pileggi GC, Zonneveld-Huijssoon E, et al. Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis. Ann Rheum Dis. 2007;66(10):1384-7. (Pubitemid 47492487)
16. Borte S, Liebert UG, Borte M, et al. Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept. Rheumatology (Oxford). 2009;48(2):144-8.
17. .•• Heijstek MW, Kamphuis S, Armbrust W, et al. Effects of the live attenuated measles-mumps-rubella booster vaccination on disease activity in patients with juvenile idiopathic arthritis: a randomized trial. JAMA. 2013;309(23):2449-56. Prospective randomised trials are rare in this field. This study confirmed the safety and immunogenicity of MMR booster vaccine for JIA patients, including those on low-dose methotrexate.
18. .•• Heijstek MW, van Gageldonk PG, Berbers GA, et al. Differences in persistence of measles, mumps, rubella, diphtheria and tetanus antibodies between children with rheumatic disease and healthy controls: a retrospective cross-sectional study. Ann Rheum Dis. 2012;71(6):948-54. This study suggests that seroprotection may wane in children with PRDs, leaving a significant proportion potentially vulnerable to VPDs as they get older. Particularly concerning was the loss of immunity to rubella.
19. Silva CA, Aikawa NE. Bonfa E Vaccinations in juvenile chronic inflammatory diseases: an update. Nat Rev Rheumatol. 2013;9(9):532-43.
20. WHO. WHO recommendations for the post-pandemic period - Pandemic (H1N1) 2009 briefing note 23. 2014; Available from: http://www.who.int/csr/disease/ swineflu/notes/briefing-20100810/en/.
21. .• Aikawa NE, Campos LM, Silva CA, et al. Glucocorticoid: major factor for reduced immunogenicity of 2009 influenza A (H1N1) vaccine in patients with juvenile autoimmune rheumatic disease. J Rheumatol. 2012;39(1):167-73.
22. .• Aikawa NE, Campos LM, Goldenstein-Schainberg C, et al. Effective seroconversion and safety following the pandemic influenza vaccination (anti-H1N1) in patients with juvenile idiopathic arthritis. Scand J Rheumatol. 2013;42(1):34-40.
23. .• Campos LM, Silva CA, Aikawa NE, et al. High disease activity: an independent factor for reduced immunogenicity of the pandemic influenza a vaccine in patients with juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2013;65(7):1121-7.
24. .• Guissa VR, Pereira RM, Sallum AM, et al. Influenza A H1N1/2009 vaccine in juvenile dermatomyositis: reduced immunogenicity in patients under immunosuppressive therapy. Clin Exp Rheumatol. 2012;30(4):583-8. This reference and references 21, 22 and 23 detail the extensive work done by this group in determining the safety and immunogenicity of influenza H1N1/2009 vaccine for children with PRDs.
25. PRevention CfDCa. Seasonal Influenza (Flu). 2014 [cited 2014 30th April]; Available from: http://www.cdc.gov/flu/protect/children.htm.
26. Aikawa NE, Trudes G, Campos LM, et al. Immunogenicity and safety of two doses of a non-adjuvanted influenza A H1N1/2009 vaccine in young autoimmune rheumatic diseases patients. Lupus. 2013;22(13):1394-8.
27. Singer NG, Wallette M, Tomanova-Soltys I, et al. Interim safety data of Gardasil in a Trial in Females with JIA and Seronegative Arthritis [Abstract]. Arthritis Rheum. 2009;60 Suppl 10:226.
28. .•• Heijstek MW, Scherpenisse M, Groot N, et al. Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study. Ann Rheum Dis. 2013. doi:10.1136/annrheumdis-2013-203429.
29. .•• Heijstek MW, Scherpenisse M, Groot N, et al. Immunogenicity of the bivalent human papillomavirus vaccine in adolescents with juvenile systemic lupus erythematosus or juvenile dermatomyositis. J Rheumatol. 2013;40(9):1626-7. This reference and reference 28 provide the only data currently available regarding immunogenicity of HPV vaccine of any type in PRDs.